CD8A and neoplasm: However, PD-1, a marker of both T-cell activation and exhaustion, may serve as a more reliable marker of ongoing antitumor immunity than CD8 alone.43 Moreover, recent publications suggest that PD-1+ and CD8+PD-1+ immune cells may represent tumor antigen–specific T cells.44-46